Adult males and females aged 18 to 65 with a diagnosis of migraine disorder who are employed and scheduled to work at least 30 hours per week during a day time shift. Patients must be treating migraines with either a combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap) or oral triptan monotherapy as prescribed prior to study start. Patients will be recruited from up to 30 investigative sites.